Cosuppression of NF-κB and AICDA Overcomes Acquired EGFR-TKI Resistance in Non-Small Cell Lung Cancer.
Min-Kyung YeoYoonjoo KimDa Hye LeeChaeuk ChungGo Eun BaePublished in: Cancers (2022)
Treatment with an EGFR-TKI plus cosuppression of NF-κB and AICDA may be a promising strategy to overcome EGFR-TKI resistance in LACs.